In anti-PD-L1 (control group) (RR 0.99, 95% CI 0.56-1.73, p = 0.96, Fig. 4d), gastric or esophagogastric cancer (RR 1.78, 95% CI 0.68-4.63, p = 0.24, Fig. 4g), lung cancer (RR 1.51, 95% CI 0.92-2.49, p = 0.10, Fig. 4h) and head and neck squamous cell carcinoma (RR 1.61, 95% CI 0.29-8.94, p = 0.58, Fig. 4i) groups, there was no statistically significant difference in ORR between ICI combination therapy and ICI monotherapy. The gene discussed is CD274; the disease is lung carcinoma.